noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Palantir Technologies Inc.

Annual Report (Form ARS)
Palantir Technologies Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)
Artificial Intelligence Technology[...]

SARA Enabled Security Selected to Protect Active Builds Across Three[...]

Healthcare

Pappas Capital LLC

06/04/2021 | Press release | Archived content

Chimerix Receives FDA Approval for TEMBEXA® (brincidofovir) for t...

News | 06. 04. 2021

Chimerix

DURHAM, N.C., June 04, 2021 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA^® (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients, including neonates.

Pappas Capital LLC published this content on June 04, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format